HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating on Innate Pharma (NASDAQ:IPHA) and maintained a price target of $11.5.
April 11, 2024 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Innate Pharma's stock rating was reiterated as Buy by HC Wainwright & Co. with a price target of $11.5.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst firm like HC Wainwright & Co. typically signals confidence in the company's future performance. This endorsement can positively influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100